Comparative Pharmacology
Head-to-head clinical analysis: DESIPRAMINE HYDROCHLORIDE versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESIPRAMINE HYDROCHLORIDE versus VIVACTIL.
DESIPRAMINE HYDROCHLORIDE vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Oral: Initial 25-75 mg/day in divided doses; increase gradually to 100-200 mg/day, maximum 300 mg/day. Usual maintenance: 100-200 mg/day single or divided doses.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal half-life 12–30 hours (mean ~22 hours); extensive interindividual variability due to CYP2D6 polymorphism.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Renal excretion of metabolites accounts for approximately 70%; fecal elimination ~30%. Unchanged drug <5% in urine.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant